SNTI (Senti Biosciences Holdings) PB Ratio: (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNTI Senti Biosciences Holdings Inc SNTI
18 GF Score
Price $0.39
! 6 Warning Signs
View Full Analysis

What is Senti Biosciences Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-26), Senti Biosciences Holdings's share price is $0.3868. Senti Biosciences Holdings's Book Value per Share for the quarter that ended in Jun. 2026 was $-0.11. Hence, Senti Biosciences Holdings's PB Ratio of today is .

The historical rank and industry rank for Senti Biosciences Holdings's PB Ratio or its related term are showing as below:

During the past 6 years, Senti Biosciences Holdings's highest PB Ratio was 13.41. The lowest was 0.11. And the median was 0.35.

SNTI's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.975
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Senti Biosciences Holdings's average Book Value Per Share Growth Rate was -111.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -81.60% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Senti Biosciences Holdings was -81.60% per year. The lowest was -81.60% per year. And the median was -81.60% per year.

Back to Basics: PB Ratio


Senti Biosciences Holdings  (NAS:SNTI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Senti Biosciences Holdings PB Ratio Related Terms


Senti Biosciences Holdings PB Ratio Historical Data

* Premium members only.

The historical data trend for Senti Biosciences Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senti Biosciences Holdings PB Ratio Chart

Senti Biosciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial 0.00 0.49 0.45 0.66 5.75

Senti Biosciences Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 4.56 5.75 9.90 0.00

SNTI vs ZEOX, BCDA, COCP: PB Ratio Comparison

For the Biotechnology subindustry, Senti Biosciences Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senti Biosciences Holdings PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Senti Biosciences Holdings's PB Ratio falls into.


SNTI
18GF Score
Senti Biosciences Holdings Inc SNTI
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senti Biosciences Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Senti Biosciences Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2026)
=0.3868/-0.109
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Senti Biosciences Holdings Business Description

Address 2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
18GF Score

Get the complete analysis for SNTI

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price